Go to content

Media

Welcome to the Medicago Media Room

Our Media Room is designed to provide reporters with the latest news, as well as key facts, figures and background information.

Press releases

May 18, 2021
Press Release
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
April 23, 2021
Press Release
Health Canada initiates the review of the rolling submission for the first Canadian-based COVID-19 vaccine candidate
March 16, 2021
Press Release
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
December 4, 2020
Press Release
Takashi Nagao appointed President and Chief Executive Officer of Medicago
November 12, 2020
Press Release
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
November 10, 2020
Press Release
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
October 23, 2020
Press Release
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
July 14, 2020
Press Release
Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate
July 8, 2020
Press Release
Dynavax and Medicago announce collaboration to develop a novel adjuvanted COVID-19 vaccine candidate
July 7, 2020
Press Release
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
May 14, 2020
Press Release
Medicago announces positive results in animal trials for its vaccine candidate against COVID-19
May 5, 2020
Press Release
Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
March 24, 2020
Press Release
Government of Canada providing financial support towards Medicago's COVID-19 vaccine development
March 21, 2020
Press Release
Government of Quebec providing $7 million towards Medicago's COVID-19 vaccine development
March 12, 2020
Press Release
Medicago announces production of a viable vaccine candidate for COVID-19
November 5, 2019
A Medicago's employee named one of CASCON x Evoke Canada's Tech Titans: Top 19 of 2019
October 1, 2019
Press Release
Medicago's New Drug Submission accepted for Scientific Review by Health Canada
April 25, 2019
Press Release
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress
March 20, 2019
Media Article
Congratulations Nathalie Landry as a finalist for the Mercuriades 2019 in the category Leadership, Outstanding Woman Sun Life Financial
December 20, 2018
Media Article
Canadian Biotech Breaking New Ground in the Fight Against Infectious Disease
October 30, 2018
Media Article
Life sciences - Québec International
September 27, 2018
Media Article
Return of U.S. Flu Season Brings Worries About a Virulent Replay (Bloomberg)
September 24, 2018
Media Article
Plant-Derived VLPs as a Novel Approach to Addressing an Unmet Need in Influenza Prevention
September 18, 2018
Press Release
Medicago officially starts the construction of its site in Estimauville's Innovation area
March 1, 2018
Media Article
This Company Is Testing a Flu Vaccine Made In Tobacco -- And Philip Morris Is On Board (Forbes)
September 26, 2017
Press Release
Medicago announces Phase 3 study of VLP Quadrivalent influenza vaccine
March 6, 2017
Press Release
Medicago's Board of Directors asked company CEO Andy Sheldon to explore new business opportunities for Medicago
October 29, 2015
Press Release
Medicago engaged by the Canadian Government to develop Ebola monoclonal antibodies
May 19, 2015
Press Release
Medicago to build $245M production facility in Quebec City

Media contacts

This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Medicago media contacts only respond to calls and emails from professional journalists.

If you are not a journalist, please visit the Contact us page to reach the appropriate Medicago contact.

Alissa Von Bargen
+1 647-234-5975
medicago.media@gcicanada.com
Contact her

Contact us

Thank you for your interest in Medicago.

If you have any questions about the following topics, please make your selection and you will be redirected to the appropriate information.

* Indicates required field.